Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Identifying Bacterial Infections in Setting of Atopic Dermatitis

Key clinical point: Identification and management of bacterial skin infections is challenging in patients with atopic dermatitis because of overlapping and masking features.

Major finding: An estimated 70% of lesional and 39% of nonlesional atopic dermatitis skin is colonized with Staphylococcus aureus.

Study details: The review is based on the most current evidence relating to bacterial infections in patients with atopic dermatitis.

Disclosures: The statement was funded in part by the senior author’s fellowships from the National Institutes of Health Research, and the International Eczema Council received sponsorship from AbbVie, Amgen, Asana Biosciences, Celgene, Chugai, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, LEO Pharma, Kyowa Kirin, Novartis, Pierre Fabre, Pfizer, Sanofi Genzyme, Regeneron Pharmaceuticals, Sienna and Valeant. Among the 16 authors, 13 have financial ties to a wide range of pharmaceutical companies, including those listed above.

Citation:

Alexander H et al. Br J Dermatol. 2019 Nov 1. doi: 10.1111/bjd.1864319.